#immuneoncia — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #immuneoncia, aggregated by home.social.
-
ImmuneOncia raises 100 billion won through rights offering to fund NK/T cell lymphoma drug development, while major shareholder Yuhan Corp. participates with only 15 billion won investment, maintaining majority control despite stake dilution from 65.75% to 56.24%
#YonhapInfomax #ImmuneOncia #YuhanCorp #CapitalIncrease #ImmunoOncology #NK/TCellLymphoma #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=113762 -
ImmuneOncia raises 100 billion won through rights offering to fund NK/T cell lymphoma drug development, while major shareholder Yuhan Corp. participates with only 15 billion won investment, maintaining majority control despite stake dilution from 65.75% to 56.24%
#YonhapInfomax #ImmuneOncia #YuhanCorp #CapitalIncrease #ImmunoOncology #NK/TCellLymphoma #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=113762 -
ImmuneOncia raises 100 billion won through rights offering to fund NK/T cell lymphoma drug development, while major shareholder Yuhan Corp. participates with only 15 billion won investment, maintaining majority control despite stake dilution from 65.75% to 56.24%
#YonhapInfomax #ImmuneOncia #YuhanCorp #CapitalIncrease #ImmunoOncology #NK/TCellLymphoma #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=113762 -
ImmuneOncia raises 100 billion won through rights offering to fund NK/T cell lymphoma drug development, while major shareholder Yuhan Corp. participates with only 15 billion won investment, maintaining majority control despite stake dilution from 65.75% to 56.24%
#YonhapInfomax #ImmuneOncia #YuhanCorp #CapitalIncrease #ImmunoOncology #NK/TCellLymphoma #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=113762 -
ImmuneOncia, Yuhan Corporation's immune-oncology subsidiary, lists on KOSDAQ, aiming for growth through technology transfers and clinical advancements in cancer treatments.
#YonhapInfomax #ImmuneOncia #YuhanCorporation #KOSDAQListing #ImmuneCancerDrugs #TechnologyTransfer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63799 -
Four companies set to debut on Korean stock markets this week, including Dalba Global and ImmuneOncia, with Keystron opening IPO subscription amid active listing activities.
#YonhapInfomax #IPOMarket #DalbaGlobal #ImmuneOncia #KOSDAQListing #KeystronSubscription #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63709